keyword
MENU ▼
Read by QxMD icon Read
search

Systemic mastocytosis

keyword
https://www.readbyqxmd.com/read/29619541/systemic-mastocytosis-identified-in-two-women-developing-fragility-fractures-during-lactation
#1
J J Zhu, D Mahendran, M H Lee, J Seah, S Fourlanos, S Varadarajan, A Ghasem-Zadeh, R J MacIsaac, E Seeman
Two women presenting with fragility fractures during lactation had bone mineral density (BMD) reduced more greatly than usually associated with lactation. The first woman was 29 years old with a BMD T-score of - 3.2 SD at the spine and- 2.0 SD at the femoral neck. The second woman was 35 years old with a BMD T-score of - 4.5 SD at the spine and - 2.8 SD at the femoral neck. Both women had increased cortical porosity and reduced trabecular density. Investigation identified an elevated serum tryptase, and marrow biopsy confirmed the diagnosis of mastocytosis...
April 4, 2018: Osteoporosis International
https://www.readbyqxmd.com/read/29618463/stone-rm-manley-pw-larson-ra-capdeville-r-midostaurin-its-odyssey-from-discovery-to-approval-for-treating-acute-myeloid-leukemia-and-advanced-systemic-mastocytosis-blood-adv-2017-2-4-444-453
#2
https://www.readbyqxmd.com/read/29602231/eosinophil-phagocytosis-in-advanced-systemic-mastocytosis-with-eosinophilia
#3
Rosario M Morales-Camacho, Sandra Villanueva-Herraiz, Concepción Prats-Martín, Juan J Borrero, Ricardo Bernal, M Teresa Vargas
No abstract text is available yet for this article.
March 30, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/29599147/systemic-mastocytosis-with-concurrent-multiple-myeloma
#4
Ashvind A Prabahran, Surender K Juneja
No abstract text is available yet for this article.
March 29, 2018: Blood
https://www.readbyqxmd.com/read/29571984/a-case-of-mast-cell-leukemia-a-review-of-the-pathophysiology-of-systemic-mastocytosis-and-associated-psychiatric-symptoms
#5
Nathan K Jamison, Emily G Holmes
No abstract text is available yet for this article.
February 12, 2018: Psychosomatics
https://www.readbyqxmd.com/read/29569284/low-frequency-of-acetyl-salicylic-acid-hypersensitivity-in-mastocytosis-the-results-of-a-double-blind-placebo-controlled-challenge-study
#6
M A W Hermans, S Q A van der Vet, P M van Hagen, R Gerth van Wijk, P L A van Daele
BACKGROUND: Patients with mastocytosis are at increased risk of anaphylaxis. The use of nonsteroidal anti-inflammatory drugs (NSAIDs) is often discouraged because of this reason. However, the actual prevalence and severity of NSAID-related hypersensitivity among patients with mastocytosis is unknown. METHODS: A double-blind, placebo-controlled acetylsalicylic acid (ASA) challenge up to a cumulative dose of 520 mg was performed among adult patients with mastocytosis...
March 22, 2018: Allergy
https://www.readbyqxmd.com/read/29567760/blatt-k-cerny-reiterer-s-schwaab-j-et-al-identification-of-the-ki-1-antigen-cd30-as-a-novel-therapeutic-target-in-systemic-mastocytosis-blood-2015-126-26-2832-2841
#7
https://www.readbyqxmd.com/read/29517164/anaphylactic-reaction-to-an-ultrasound-contrast-agent-lumason-in-a-patient-with-systemic-mastocytosis
#8
Michael C Olson, Thomas D Atwell, John M Knudsen
Severe adverse reactions to ultrasound (US) contrast agents are rare, and only a few cases of anaphylaxis following the administration of US contrast agents have been reported, often without a defined etiology. We present a case of anaphylactic reaction to the injection of an US contrast agent in a patient with systemic mastocytosis, which highlights the disorder as a possible risk factor warranting additional consideration prior to performing a contrast-enhanced US examination.
March 8, 2018: Journal of Clinical Ultrasound: JCU
https://www.readbyqxmd.com/read/29487059/midostaurin-its-odyssey-from-discovery-to-approval-for-treating-acute-myeloid-leukemia-and-advanced-systemic-mastocytosis
#9
REVIEW
Richard M Stone, Paul W Manley, Richard A Larson, Renaud Capdeville
Midostaurin was a prototype kinase inhibitor, originally developed as a protein kinase C inhibitor and subsequently as an angiogenesis inhibitor, based on its inhibition of vascular endothelial growth factor receptor. Despite promising preclinical data, early clinical trials in multiple diseases showed only modest efficacy. In 1996, the relatively frequent occurrence of fms-like tyrosine kinase 3 ( FLT3 ) activating mutations in acute myeloid leukemia (AML) was first recognized. Several years later, midostaurin was discovered to be a potent inhibitor of the FLT3 tyrosine kinase and to have activity against mutant forms of KIT proto-oncogene receptor tyrosine kinase, which drive advanced systemic mastocytosis (SM)...
February 27, 2018: Blood Advances
https://www.readbyqxmd.com/read/29481892/concurrent-ige-mediated-nmba-allergy-in-systemic-mastocytosis
#10
Pascale Dewachter, Claudie Mouton-Faivre
No abstract text is available yet for this article.
February 23, 2018: Annals of Allergy, Asthma & Immunology
https://www.readbyqxmd.com/read/29469787/telangiectasia-macularis-eruptiva-perstans-associated-with-a-sicca-complex
#11
Ramone Faith Williams, Rosalynn M Nazarian, Gideon P Smith
We present the case of woman in her 50s who developed numerous red-brown telangiectatic macules on her trunk and extremities, as well as persistent dry eyes and dry mouth. Skin biopsy was consistent with telangiectasia macularis eruptiva perstans (TMEP). Serum tryptase was elevated suggesting systemic involvement. Anti-Ro and La were negative. ANA was positive. Salivary gland biopsy revealed a focus score of 3 and immunostains revealed infiltrates of aberrant CD117 positive mast cells. This case suggests a mechanistic role of mastocytosis in salivary compromise...
October 15, 2017: Dermatology Online Journal
https://www.readbyqxmd.com/read/29466766/recent-advances-in-the-genomics-and-therapy-of-bcr-abl1-positive-and-negative-chronic-myeloproliferative-neoplasms
#12
REVIEW
Tariq I Mughal, Jason Gotlib, Ruben Mesa, Steffen Koschmieder, H Jean Khoury, Jorge E Cortes, Tiziano Barbui, Rüdiger Hehlmann, Michael Mauro, Susanne Saussele, Jerald P Radich, Richard A Van Etten, Giuseppe Saglio, Srdnan Verstovek, Robert Peter Gale, Omar Abdel-Wahab
This review is based on the presentations and deliberations at the 7th John Goldman Chronic Myeloid Leukemia (CML) and Myeloproliferative Neoplasms (MPN) Colloquium which took place in Estoril, Portugal on the 15th October 2017, and the 11th post-ASH International Workshop on CML and MPN which took place on the 6th-7th December 2016, immediately after the 58th American Society of Hematology Annual Meeting. Rather than present a resume of the proceedings, we have elected to address some of the topical translational research and clinically relevant topics in greater detail...
February 14, 2018: Leukemia Research
https://www.readbyqxmd.com/read/29460435/topical-pimecrolimus-for-paediatric-cutaneous-mastocytosis
#13
J Mashiah, A Harel, C Bodemer, S Hadj-Rabia, I Goldberg, E Sprecher, A Kutz
BACKGROUND: Most cases of paediatric cutaneous mastocytosis (CM) occur before the age of 2 years, and regression occurs in only 67% of children. Given the absence of any specific therapy, CM is usually treated symptomatically. A few publications have reported the beneficial effect of calcineurin inhibitors for CM. AIM: We sought to evaluate the clinical effectiveness and safety profile of topical pimecrolimus cream for the treatment of CM. METHODS: We performed a retrospective study of all diagnosed cases of CM treated with topical pimecrolimus 1% cream between 2013 and 2015...
February 20, 2018: Clinical and Experimental Dermatology
https://www.readbyqxmd.com/read/29458385/de-novo-mast-cell-leukemia-without-cd25-expression-and-kit-mutations-a-rare-case-report-in-a-13-year-old-child
#14
Yalin Zheng, Lin Nong, Li Liang, Wei Wang, Ting Li
BACKGROUND: Mast cell leukemia (MCL) is a very rare form of systemic mastocytosis (SM) and accounts for less than 0.5% of all mastocytosis. The diagnosis of MCL requires the presence of SM criteria, accompanied by leukemic infiltrating of atypical mast cells (MCs) in bone marrow (BM), peripheral blood as well as extracutaneous organs. MCL is a fatal disease that almost always behaves aggressively, and the median survival time is only about six months. Herein, we present a rare case of de novo MCL without CD25 expression and KIT mutations...
February 20, 2018: Diagnostic Pathology
https://www.readbyqxmd.com/read/29451318/effective-management-of-severe-cutaneous-mastocytosis-in-young-children-with-omalizumab-xolair-%C3%A2
#15
J D M Hughes, T Olynyc, H Chapdelaine, L Segal, B Miedzybrodzki, M Ben-Shoshan
Omalizumab (Xolair ® ) is an anti-IgE monoclonal antibody, which may benefit adults with systemic mastocytosis. We report effective treatment with omalizumab in two toddlers with severe diffuse cutaneous mastocytosis. Our cases offer preliminary evidence to support the safe use of omalizumab in paediatric patients with cutaneous mastocytosis.
February 16, 2018: Clinical and Experimental Dermatology
https://www.readbyqxmd.com/read/29439183/the-kit-and-pdgfra-switch-control-inhibitor-dcc-2618-blocks-growth-and-survival-of-multiple-neoplastic-cell-types-in-advanced-mastocytosis
#16
Mathias Schneeweiss, Barbara Peter, Siham Bibi, Gregor Eisenwort, Dubravka Smiljkovic, Katharina Blatt, Mohamad Jawhar, Daniela Berger, Gabriele Stefanzl, Susanne Herndlhofer, Georg Greiner, Gregor Hoermann, Emir Hadzijusufovic, Karoline V Gleixner, Peter Bettelheim, Klaus Geissler, Wolfgang R Sperr, Andreas Reiter, Michel Arock, Peter Valent
Systemic mastocytosis is a complex disease defined by abnormal growth and accumulation of neoplastic mast cells in various organs. Most patients exhibit a D816V-mutated variant of KIT, which confers resistance against imatinib. Clinical problems in systemic mastocytosis arise from mediator-related symptoms and/or organ destruction caused by malignant expansion of neoplastic mast cells and/or other myeloid cells in various organ systems. DCC-2618 is a spectrum-selective pan KIT and PDGFRA inhibitor which blocks KIT D816V and multiple other kinase-targets relevant to systemic mastocytosis...
February 8, 2018: Haematologica
https://www.readbyqxmd.com/read/29435387/systemic-mastocytosis-the-difficult-patient-with-a-rare-disease-case-presentation-and-brief-review
#17
Daniel H Desmond, Mark G Carmichael
Mastocytosis is a rare process involving the activation and accumulation of clonal mast cells categorized by cutaneous or systemic involvement. Although the diagnosis of cutaneous disease can be straightforward and confirmed via skin biopsy, systemic disease mimics more common disease processes making diagnosis a challenge. The widespread physiologic distribution of mast cells causes a variety of symptoms with aberrant expression including fatigue, headache, depression, dyspnea, dyspepsia, nausea, and abdominal pain...
February 2018: Hawai'i Journal of Medicine & Public Health: a Journal of Asia Pacific Medicine & Public Health
https://www.readbyqxmd.com/read/29431216/mast-cell-neural-interactions-contribute-to-pain-and-itch
#18
REVIEW
Kalpna Gupta, Ilkka T Harvima
Mast cells are best recognized for their role in allergy and anaphylaxis, but increasing evidence supports their role in neurogenic inflammation leading to pain and itch. Mast cells act as a "power house" by releasing algogenic and pruritogenic mediators, which initiate a reciprocal communication with specific nociceptors on sensory nerve fibers. Consequently, nerve fibers release inflammatory and vasoactive neuropeptides, which in turn activate mast cells in a feedback mechanism, thus promoting a vicious cycle of mast cell and nociceptor activation leading to neurogenic inflammation and pain/pruritus...
March 2018: Immunological Reviews
https://www.readbyqxmd.com/read/29426921/the-2016-who-classification-and-diagnostic-criteria-for-myeloproliferative-neoplasms-document-summary-and-in-depth-discussion
#19
REVIEW
Tiziano Barbui, Jürgen Thiele, Heinz Gisslinger, Hans Michael Kvasnicka, Alessandro M Vannucchi, Paola Guglielmelli, Attilio Orazi, Ayalew Tefferi
The new edition of the 2016 World Health Organization (WHO) classification system for tumors of the hematopoietic and lymphoid tissues was published in September 2017. Under the category of myeloproliferative neoplasms (MPNs), the revised document includes seven subcategories: chronic myeloid leukemia, chronic neutrophilic leukemia, polycythemia vera (PV), primary myelofibrosis (PMF), essential thrombocythemia (ET), chronic eosinophilic leukemia-not otherwise specified and MPN, unclassifiable (MPN-U); of note, mastocytosis is no longer classified under the MPN category...
February 9, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/29405310/development-and-validation-of-the-mastocytosis-activity-score
#20
F Siebenhaar, B Sander, L H T Ho, A Ellrich, M Maurer, K Weller
BACKGROUND: Mastocytosis is a heterogeneous disease characterized by a clonal expansion of mast cells in various organs. The vast majority of patients suffer from signs and symptoms caused by mediator release from mast cells. Although the disease burden is high, there is currently no specific and validated instrument to measure and monitor signs and symptoms in patients with mastocytosis. OBJECTIVE: To develop and validate a disease-specific tool to measure and monitor the activity of signs and symptoms in patients with mastocytosis, the Mastocytosis Activity Score (MAS)...
February 6, 2018: Allergy
keyword
keyword
29516
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"